Skip to main content
. 2019 Mar 18;21(4):537–546. doi: 10.1093/neuonc/noy202

Fig. 4.

Fig. 4.

Kaplan‒Meier analysis of overall survival and progression-free survival. (A) Median OS was 8.9 months for dose level 1 and 25.3 months for dose level 2. (B) Median PFS was 5.8 months for dose level 1 and 8.9 months for dose level 2.